Northstar Pharmacogenomics (PGx)™
Support safer chemotherapy dosing decisions.
Northstar PGx Accuracy1
Focused pharmacogenomic testing available as an add-on to Northstar Select®.
What is Pharmacogenomics (PGx)?
Pharmacogenomics (PGx) evaluates genetic factors that affect how an individual metabolizes certain medications. These differences can influence how a drug is processed in the body. Recent developments in this field specific to oncology have brought renewed focus, powered by FDA safety label changes and oncology care guidelines recognizing the importance of broader testing.
More informed discussions without delaying care.
Chemotherapy dosing decisions are often made quickly and alongside other treatment considerations. Without insight into how a patient metabolizes certain drugs, standard dosing can increase the risk of severe toxicity or unexpected adverse reactions.
The Northstar PGx reports, from the same blood sample, a patient's predicted metabolizer status and associated clinical implications to help inform treatment planning without extending turnaround time. Recent changes to guidelines emphasize the importance of broader testing to avoid potential chemotherapy toxicity (i.e. DPD deficiency testing prior to prescribing capecitabine or fluorouracil (5-FU)1). By integrating pharmacogenomic context directly into the liquid biopsy workflow, Northstar PGx supports more informed discussions around dosing, monitoring, and treatment planning—without delaying care.
How Northstar PGx™ works
Northstar PGx™ provides focused pharmacogenomic testing integrated directly into the Northstar Select® testing workflow.
What clinicians receive
Genotype and metabolizer status
for clinically actionable PGx variants
Curated clinical implications
through easy-to-interpret reporting
No external
send-outs
or additional coordination
Seamless delivery
of PGx results alongside Northstar Select Findings
Download Helpful Resources
BillionToOne internal data on file, Jan 2026
“FDA Highlights Importance of DPD Deficiency Discussions With Patients Prior to Capecitabine or 5FU Treatment.” The ASCO Post, 28 Jan. 2025
More answers start here.
